The PD-1-blocking antibody pembrolizumab has been shown to elicit an increased proliferation of both, Foxp3-negative and Foxp3-positive CD4 as well as CD8 T cells in stage IV melanoma patients, displaying the most significant effects in the PD-1 expressing cells of these populations [237]. This evidence concerns the gene CD8A and melanoma.